A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT06731075
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT06731075
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06731075. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2027-04-25 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- ORMD-0801 8 mg
- Intervention (Other)
- Placebo capsule
- Intervention (Drug)
- ORMD-0801 16 mg
- Lead sponsor
- Oramed, Ltd.
- Collaborator
- InClin, Inc.
Record details
- Record id
cardio:ct-nct06731075- Content hash
63264bc09ed00ac2c479358b168131ae40338c9e5b09061a5714c24676285dcc